Some examples of this broader use are the use of VenAza in patients diagnosed with R/R or AML evolving from MPN [9], in patients diagnosed with higher risk MDS, in triplets including FLT3i, IDHi or menin-inhibitors [10–12] FLT3 [13, 14]), in combination with standard chemotherapy in different subsets of patients diagnosed with AML [15–17], or as maintenance strategies) [18–21]. Here, FLT3 is linked to acute myeloid leukemia.